Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn
- PMID: 12496219
- PMCID: PMC1755998
- DOI: 10.1136/fn.88.1.f6
Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn
Abstract
Objectives: To assess the effectiveness of high dose intravenous immunoglobulin (HDIVIG) in reducing the need for exchange transfusion in neonates with proven haemolytic disease due to Rh and/or ABO incompatibility. To assess the effectiveness of HDIVIG in reducing the duration of phototherapy and hospital stay.
Design: Systematic review of randomised and quasi-randomised controlled trials comparing HDIVIG and phototherapy with phototherapy alone in neonates with Rh and/or ABO incompatibility.
Results: Significantly fewer infants required exchange transfusion in the HDIVIG group (relative risk (RR) 0.28 (95% confidence interval (CI) 0.17 to 0.47); number needed to treat 2.7 (95% CI 2.0 to 3.8)). Also hospital stay and duration of phototherapy were significantly reduced.
Conclusion: HDIVIG is an effective treatment.
Figures






Comment in
-
Late anaemia in Rh haemolytic disease.Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F444; author reply F445. doi: 10.1136/fn.88.5.f444. Arch Dis Child Fetal Neonatal Ed. 2003. PMID: 12937058 Free PMC article. No abstract available.
-
High dose intravenous immunoglobulin in haemolytic disease of neonates.Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F444-5; author reply F445. doi: 10.1136/fn.88.5.f444-b. Arch Dis Child Fetal Neonatal Ed. 2003. PMID: 12937059 Free PMC article. No abstract available.
-
Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.Arch Dis Child Fetal Neonatal Ed. 2003 Sep;88(5):F444; author reply F445. doi: 10.1136/fn.88.5.f444-a. Arch Dis Child Fetal Neonatal Ed. 2003. PMID: 12937060 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical